Pharmacy

POSEIDON updates boost treatment potential of tremelimumab-durvalumab-CT for mNSCLC

Audrey Abella, 4 hours ago

In the updated analysis of the POSEIDON trial presented at ESMO 2022, the combination regimen comprising tremelimumab, durvalumab, and chemotherapy (T+D+CT) used in the first-line setting conferred long-term overall survival (OS) benefit in individuals with metastatic non-small-cell lung cancer (mNSCLC).

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

Elvira Manzano, 14 hours ago

The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

Add-on apatinib puts brakes on disease progression in advanced TNBC

20 hours ago

The addition of apatinib to vinorelbine appears to prolong progression-free survival in patients with advanced triple-negative breast cancer (TNBC) with failed first- or second-line treatment, as shown in the results of a phase II study.

Infliximab reintroduction effective in some Crohn's disease patients

Stephen Padilla, Yesterday

Retreatment with infliximab (IFX) appears safe and effective in nearly a third of patients with Crohn’s disease (CD), independent of the reason for prior discontinuation, results of a study have shown.

5-fluorouracil plus heparin no better than placebo in preventing proliferative vitreoretinopathy

Yesterday

Adjuvant therapy with 5-fluorouracil and low-molecular weight heparin (LMWH) is not superior to placebo in the prevention of proliferative vitreoretinopathy (PVR) in eyes with rhegmatogenous retinal detachment (RRD), reports a study.

PLD-apatinib combo show promise for ovarian cancer

Audrey Abella, Yesterday

A combination regimen comprising apatinib, a small-molecule TKI*, and pegylated liposomal doxorubicin (PLD) led to improved progression-free survival (PFS) in women with platinum-resistant recurrent ovarian cancer (PROC), results of the APPROVE trial suggest.

Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF

Elvira Manzano, 04 Oct 2022

$Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum$

Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum

06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Brensocatib has no impact on COVID-19 clinical outcomes

Roshini Claire Anthony, 02 Oct 2022

Results of the STOP-COVID trial, presented at ERS 2022, showed no clinical outcome benefit with the dipeptidyl peptidase-1 (DPP-1) inhibitor brensocatib compared with placebo in patients hospitalized with COVID-19 in the UK.

Inhaled IFN-β1a shows favourable signals for hospitalized COVID-19 patients

Audrey Abella, 22 Sep 2022

In the phase III SPRINTER trial, inhaled interferon-beta-1a (IFN-β1a) showed encouraging signals for preventing disease progression or death in hospitalized COVID-19 patients.

Tezepelumab reduces mucus plugging in patients with asthma

Elaine Soliven, 22 Sep 2022

In patients with uncontrolled, moderate-to-severe asthma, tezepelumab reduced mucus plugging, which was also tied to improvements in lung function parameters, according to an exploratory post hoc analysis of the CASCADE* trial presented at ERS 2022.

ALLEGRO-LT shows long-term benefit of ritlecitinib for alopecia areata

Audrey Abella, 21 Sep 2022

In the interim analysis of the ongoing phase III ALLEGRO-LT trial, the investigational oral JAK3*/TEC inhibitor ritlecitinib demonstrated long-term safety and remarkable scalp hair regrowth in adults and adolescents with alopecia areata (AA).

Antibiotics for COPD exacerbations: Aye or nay?

Elvira Manzano, 21 Sep 2022

Antibiotics cannot be withheld in patients with chronic obstructive pulmonary disease (COPD) seeking treatment for acute moderate exacerbations, suggests findings from the ABACOPD study presented at ERS 2022. However, in one subgroup, it appeared antibiotics can be ruled out.

Remote smoking cessation programme delivers encouraging results in high-risk individuals

Roshini Claire Anthony, 20 Sep 2022

A smoking cessation intervention delivered via telephone resulted in greater smoking cessation rates than usual care among individuals enrolled in targeted lung health screening, according to results of the QuLIT*2 study from the UK presented at ERS 2022.